NGF monoclonal antibody DS002 alleviates chemotherapy-induced peripheral neuropathy in rats

Autor:	Zhi-Juan, Liang, Jie, Tan, Lei, Tang, Zuo-Bin, Xie, Gan-Jun, Chen, Guo-Jian, Liu, Lin, Yuan, Kai-Xin, Wang, Hua-Ping, Ding, Hong, Qiu, Qi, Wang, Gui-Feng, Wang, Yi-Li, Chen, Chun-He, Wang
Rok vydání:	2022
Předmět:	Pharmacology Nerve Growth Factor Quality of Life Animals Antibodies Monoclonal Peripheral Nervous System Diseases Pain Antineoplastic Agents Pharmacology (medical) General Medicine Receptor trkA Rats
Zdroj:	Acta Pharmacologica Sinica. 43:2841-2847
ISSN:	1745-7254 1671-4083
DOI:	10.1038/s41401-022-00904-8
Popis:	Chemotherapy-induced peripheral neuropathy (CIPN) is one of the pervasive side effects of chemotherapy, leading to poor quality of life in cancer patients. Discovery of powerful analgesics for CIPN is an urgent and substantial clinical need. Nerve growth factor (NGF), a classic neurotrophic factor, has been identified as a potential therapeutic target for pain. In this study, we generated a humanized NGF monoclonal antibody (DS002) that most effectively blocked the interaction between NGF and tropomyosin receptor kinase A (TrkA). We showed that DS002 blocked NGF binding to TrkA in a dose-dependent manner with an IC
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2e1f5a6e6d0f7d170a8e71b4fc7053e https://doi.org/10.1038/s41401-022-00904-8 Zobrazit plný text záznamu Full text from SpringerLink